Advances in Closed-Loop Insulin Delivery Systems in Patients with Type 1 Diabetes

Vikash Dadlani; Jordan E. Pinsker; Eyal Dassau; Yogish C. Kudva

doi:10.1007/s11892-018-1051-z

Advances in Closed-Loop Insulin Delivery Systems in Patients with Type 1 Diabetes

Vikash Dadlani, Jordan E. Pinsker, Eyal Dassau, Yogish C. Kudva

Endocrinology, Diabetes, Metabolism, and Nutrition

Research output: Contribution to journal › Review article › peer-review

14 Scopus citations

Abstract

Purpose of Review: To provide a current review of closed-loop insulin delivery or artificial pancreas (AP) as therapy for people with type 1 diabetes mellitus (T1D) Recent Findings: The Medtronic Minimed 670G AP system has been in use in clinical practice since March 2017. Currently, Medtronic is conducting a large randomized clinical trial to evaluate its efficacy further in T1D. Simultaneously, the NIH has funded four research consortia to accelerate progress to approval of other AP and decision support systems. Several research groups are currently developing next-generation AP systems, with a number of companies moving toward releasing closed-loop systems in the future. AP systems are also being tested in select populations such as hypoglycemia-unaware T1D and pregnant T1D. Summary: AP research is rapidly advancing. The clinical range of AP will be expanded in the next decade.

Original language	English (US)
Article number	88
Journal	Current diabetes reports
Volume	18
Issue number	10
DOIs	https://doi.org/10.1007/s11892-018-1051-z
State	Published - Oct 1 2018

Keywords

Artificial pancreas
Closed loop
Glycemic variability
Hypoglycemia
Type 1 diabetes

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism

Access to Document

10.1007/s11892-018-1051-z

Cite this

@article{89c2f6a0f713480eb8fea5ef36f0aeed,

title = "Advances in Closed-Loop Insulin Delivery Systems in Patients with Type 1 Diabetes",

abstract = "Purpose of Review: To provide a current review of closed-loop insulin delivery or artificial pancreas (AP) as therapy for people with type 1 diabetes mellitus (T1D) Recent Findings: The Medtronic Minimed 670G AP system has been in use in clinical practice since March 2017. Currently, Medtronic is conducting a large randomized clinical trial to evaluate its efficacy further in T1D. Simultaneously, the NIH has funded four research consortia to accelerate progress to approval of other AP and decision support systems. Several research groups are currently developing next-generation AP systems, with a number of companies moving toward releasing closed-loop systems in the future. AP systems are also being tested in select populations such as hypoglycemia-unaware T1D and pregnant T1D. Summary: AP research is rapidly advancing. The clinical range of AP will be expanded in the next decade.",

keywords = "Artificial pancreas, Closed loop, Glycemic variability, Hypoglycemia, Type 1 diabetes",

author = "Vikash Dadlani and Pinsker, {Jordan E.} and Eyal Dassau and Kudva, {Yogish C.}",

note = "Publisher Copyright: {\textcopyright} 2018, Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2018",

month = oct,

day = "1",

doi = "10.1007/s11892-018-1051-z",

language = "English (US)",

volume = "18",

journal = "Current diabetes reports",

issn = "1534-4827",

publisher = "Current Medicine Group",

number = "10",

}

TY - JOUR

T1 - Advances in Closed-Loop Insulin Delivery Systems in Patients with Type 1 Diabetes

AU - Dadlani, Vikash

AU - Pinsker, Jordan E.

AU - Dassau, Eyal

AU - Kudva, Yogish C.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Purpose of Review: To provide a current review of closed-loop insulin delivery or artificial pancreas (AP) as therapy for people with type 1 diabetes mellitus (T1D) Recent Findings: The Medtronic Minimed 670G AP system has been in use in clinical practice since March 2017. Currently, Medtronic is conducting a large randomized clinical trial to evaluate its efficacy further in T1D. Simultaneously, the NIH has funded four research consortia to accelerate progress to approval of other AP and decision support systems. Several research groups are currently developing next-generation AP systems, with a number of companies moving toward releasing closed-loop systems in the future. AP systems are also being tested in select populations such as hypoglycemia-unaware T1D and pregnant T1D. Summary: AP research is rapidly advancing. The clinical range of AP will be expanded in the next decade.

AB - Purpose of Review: To provide a current review of closed-loop insulin delivery or artificial pancreas (AP) as therapy for people with type 1 diabetes mellitus (T1D) Recent Findings: The Medtronic Minimed 670G AP system has been in use in clinical practice since March 2017. Currently, Medtronic is conducting a large randomized clinical trial to evaluate its efficacy further in T1D. Simultaneously, the NIH has funded four research consortia to accelerate progress to approval of other AP and decision support systems. Several research groups are currently developing next-generation AP systems, with a number of companies moving toward releasing closed-loop systems in the future. AP systems are also being tested in select populations such as hypoglycemia-unaware T1D and pregnant T1D. Summary: AP research is rapidly advancing. The clinical range of AP will be expanded in the next decade.

KW - Artificial pancreas

KW - Closed loop

KW - Glycemic variability

KW - Hypoglycemia

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85052551981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052551981&partnerID=8YFLogxK

U2 - 10.1007/s11892-018-1051-z

DO - 10.1007/s11892-018-1051-z

M3 - Review article

C2 - 30159816

AN - SCOPUS:85052551981

SN - 1534-4827

VL - 18

JO - Current diabetes reports

JF - Current diabetes reports

IS - 10

M1 - 88

ER -

Advances in Closed-Loop Insulin Delivery Systems in Patients with Type 1 Diabetes

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this